MNPR
Monopar Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Monopar begins rolling NDA submission for ALXN1840 in Wilson diseaseJul 22, 2026
- Monopar Therapeutics received FDA Rare Pediatric Disease designation for ALXN1840 in Wilson diseaseJul 1, 2026
- Monopar publishes Phase 2 data showing ALXN1840 significantly improves copper balance in Wilson disease patientsMay 20, 2026
- Monopar to present new long-term neurological efficacy and safety data for ALXN1840 in Wilson disease at 150th American Neurological Association annual meetingSep 15, 2025
- Monopar and EDNOC announce expanded access program for MNPR-101-Zr and MNPR-101-Lu in advanced cancersJun 11, 2025